Neumora Therapeutics, Inc. (NMRA) Gets a Buy From Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings
RBC Capital Reiterates Outperform on Neumora Therapeutics, Maintains $31 Price Target
RBC Capital Remains a Buy on Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings
Neumora Therapeutics Analyst Ratings
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From RBC Capital
Stifel Nicolaus Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)
Deutsche Bank Initiates Coverage On Neumora Therapeutics With Hold Rating, Announces Price Target of $13
JP Morgan Maintains Overweight on Neumora Therapeutics, Lowers Price Target to $20
Neumora Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Sanofi (OtherSNYNF) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Started With Buy Ratings at Several Wall Street Firms
Neumora Therapeutics (NMRA.US) was covered by B of A Securities for the first time, and was given a buy rating, with a target price of $18.00.
Neumora Therapeutics (NMRA.US) was covered by Komo for the first time and was given an increase in holdings rating, with a target price of $21.00.
Neumora Therapeutics (NMRA.US) was first covered by Guggenheim and given a buy rating, with a target price of $22.00.
Neumora Therapeutics (NMRA.US) was covered by Stifel for the first time, giving it a buy rating, with a target price of $26.00.
No Data